Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Genetic profiles separate early, late autism diagnoses
Age at diagnosis reflects underlying differences in common genetic variants and developmental trajectories among people with autism.
Genetic profiles separate early, late autism diagnoses
Age at diagnosis reflects underlying differences in common genetic variants and developmental trajectories among people with autism.
To persist, memories surf molecular waves from thalamus to cortex
During the later stages of learning, the mouse brain progressively activates transcriptional regulators that drive memory consolidation.
To persist, memories surf molecular waves from thalamus to cortex
During the later stages of learning, the mouse brain progressively activates transcriptional regulators that drive memory consolidation.
Sex hormone boosts female rats’ sensitivity to unexpected rewards
During the high-estradiol stages of their estrus cycle, female rats learn faster than they do during other stages—and than male rats overall—thanks to a boost in their dopaminergic response to reward, a new study suggests.
Sex hormone boosts female rats’ sensitivity to unexpected rewards
During the high-estradiol stages of their estrus cycle, female rats learn faster than they do during other stages—and than male rats overall—thanks to a boost in their dopaminergic response to reward, a new study suggests.